16234567

Source:http://linkedlifedata.com/resource/pubmed/id/16234567

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0013089, umls-concept:C0021735, umls-concept:C0034656, umls-concept:C0280580, umls-concept:C0282461, umls-concept:C0338118, umls-concept:C1519810, umls-concept:C1521750, umls-concept:C2239176
pubmed:issue	20
pubmed:dateCreated	2005-10-19
pubmed:abstractText	Single-agent doxorubicin has been widely used to treat unresectable hepatocellular carcinoma (HCC), but the response rate is low (< 20%) and there is no convincing evidence for improved survival. Cisplatin, interferon, doxorubicin, and fluorouracil (PIAF) used in combination, by contrast, has shown promise in a phase II study. We compared doxorubicin to PIAF in patients with unresectable HCC in a phase III trial.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7503089
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibiotics, Antineoplastic, http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil, http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b
pubmed:status	MEDLINE
pubmed:month	Oct
pubmed:issn	1460-2105
pubmed:author	pubmed-author:CaoL XLX, pubmed-author:ChanAnthony TAT, pubmed-author:HoWing MWM, pubmed-author:JohnsonPhilip JPJ, pubmed-author:KohJaneJ, pubmed-author:LaiPaul B SPB, pubmed-author:LamKwok CKC, pubmed-author:LauWan YWY, pubmed-author:LeungThomas W TTW, pubmed-author:MaBrigetteB, pubmed-author:MoFrankie K FFK, pubmed-author:MokTony STS, pubmed-author:TangAmandaA, pubmed-author:WongHerman THT, pubmed-author:YeoWinnieW, pubmed-author:YuSimon C HSC, pubmed-author:ZeeBennyB
pubmed:issnType	Electronic
pubmed:day	19
pubmed:volume	97
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1532-8
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:16234567-Adult, pubmed-meshheading:16234567-Aged, pubmed-meshheading:16234567-Antibiotics, Antineoplastic, pubmed-meshheading:16234567-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:16234567-Carcinoma, Hepatocellular, pubmed-meshheading:16234567-Cisplatin, pubmed-meshheading:16234567-Doxorubicin, pubmed-meshheading:16234567-Drug Administration Schedule, pubmed-meshheading:16234567-Female, pubmed-meshheading:16234567-Fluorouracil, pubmed-meshheading:16234567-Hong Kong, pubmed-meshheading:16234567-Humans, pubmed-meshheading:16234567-Interferon-alpha, pubmed-meshheading:16234567-Liver Neoplasms, pubmed-meshheading:16234567-Male, pubmed-meshheading:16234567-Middle Aged, pubmed-meshheading:16234567-Patient Selection, pubmed-meshheading:16234567-Proportional Hazards Models, pubmed-meshheading:16234567-Prospective Studies, pubmed-meshheading:16234567-Recombinant Proteins, pubmed-meshheading:16234567-Survival Analysis, pubmed-meshheading:16234567-Treatment Outcome
pubmed:year	2005
pubmed:articleTitle	A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
pubmed:affiliation	Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China.
pubmed:publicationType	Journal Article, Clinical Trial, Randomized Controlled Trial, Clinical Trial, Phase III